ChemoCentryx Securities Settlement
No proof required
The plaintiffs that ChemoCentryx violated federal securities laws by overstating the safety and efficacy of its autoimmune disease drug, Tavneos, and misleading investors about its communications with the FDA. Affected investors who submit a valid claim form will receive a cash distribution to compensate for financial damages suffered when the company's stock value plummeted.
Payout amount
Amount TBD
Deadline to claim
Expired
Eligibility
You may qualify if: • You must have purchased or otherwise acquired ChemoCentryx common stock. • Your investment transactions must have occurred during the designated class window. • You must have suffered financial damages as a direct result of these stock purchases.
Representing law firm
Kroll Settlement Administration LLC(CCS)
https://www.chemocentryxsecuritieslitigation.com/
